Latest Share Chat

IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Mon, 22nd Jan 2024 12:19

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Syncona has an 18% stake in Autolus.

Current stock price: 117.05 pence, down 0.3% on Monday

12-month change: down 31%

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Related Shares

More News

17 May 2024 14:34

Syncona notes Autolus's first quarter loss widens amid higher costs

(Alliance News) - Syncona Ltd on Friday noted that Autolus Therapeutics PLC reported an increased loss amid higher operating costs.

9 May 2024 13:58

IN BRIEF: Syncona's Freeline gets positive results for Gaucher disease

Syncona Ltd on Thursday - London-based investor in healthcare companies - Says UK portfolio company Freeline Therapeutics Ltd presents positive new da...

9 May 2024 11:19

Syncona reports positive findings from investee Freeline

(Sharecast News) - Life science investor Syncona reported positive findings from its portfolio company Freeline Therapeutics on Thursday, after a phas...

3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

11 Apr 2024 14:22

Syncona agrees to sell stake in investee company for GBP7.4 million

(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Th...